PARP inhibitor, SBRT, and immunotherapy for advanced sarcoma
Part of Cancer clinical trials.
This trial tests a combination of a PARP inhibitor drug, targeted radiation (SBRT), and immunotherapy for people with advanced sarcoma that has spread. It aims to see if this triple therapy can shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have high-grade bone or soft tissue sarcoma that has spread or cannot be removed by surgery.
- You have already had at least one type of cancer treatment (like chemotherapy), but you have not taken a PARP inhibitor drug.
- You are between 10 and 70 years old.
- You have at least one tumor that can be measured on scans and can be treated with a special type of radiation called SBRT.
- Your doctor expects you to live more than 24 weeks (about 6 months).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of paclitaxel polymer micelles with other drugs for people with advanced bone or soft tissue sarcoma that has worsened after first-line chemotherapy. The goal is to see if this new formulation can help shrink tumors or slow their growth.
This trial tests whether combining seed radiation (iodine-125 placed in/near the tumor) with fluzoparib can better control advanced, hard-to-remove soft tissue sarcoma. It may help shrink tumors and slow progression, but you must meet several cancer, health, and safety requirements.
This trial tests a combination of two drugs, palbociclib and pembrolizumab, in people with certain types of advanced sarcoma (cancer of the soft tissues) that have continued to grow despite prior treatment. It aims to see if this combination can shrink tumors or slow down the cancer.
This Phase 2 trial tests a highly focused radiation treatment to shrink sarcoma that has spread to a limited number of spots in the body. It may help control disease while limiting radiation to healthier tissue.
This study tests a combination of chemo medicines (gemcitabine, doxorubicin, docetaxel) plus an immunotherapy drug (nivolumab) for advanced sarcoma that can’t be removed with surgery. It may help shrink tumors and slow disease growth in people whose cancer has already been treated and is measurable on scans.
This trial tests whether giving pembrolizumab along with chemotherapy delivered directly into an arm or leg (isolated limb infusion) can shrink sarcoma tumors. It is for people with advanced or metastatic sarcoma in an arm or leg who can safely have this local treatment.
Hear when a new Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.